Could you please expand on your statement about second-trimester stillbirth as an indication for progestogen prophylaxis? Is this regardless of the etiology of the stillbirth?
Question 3:
In your practice, how would you treat a woman receiving 17 alpha-hydroxyprogesterone caproate for a prior preterm delivery who shows cervical shortening at her 26-week O'Brien et al, Ultrasound Obstet Gynecol 2007; 30:687-96) .
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Question 4:
If a clinic chooses universal transabdominal screening of cervical length between 18 weeks and 24 weeks, is there an ideal time to aim for during that window? What patient characteristics decrease the accuracy of the transabdominal measurement compared with the transvaginal?
Response from Dr. Iams:
This is another question for which there is no evidence-based answer. The later one does a cervical sonogram, the more likely one is to find all who have short cervixes; however, the later one initiates treatment, the less likely one is to be successful with the "progestogen" treatment (see Markham et al, Obstet Gynecol 2014; 123:34-9 Friedman et al, Am J Obstet Gynecol 2013; 208:190.e1-7.) .
Question 5:
Do you recommend any variation in screening or management in the patient with cervical shortening due to LEEP/cone history versus other risk factors?
Response from Dr. Iams:
No (see Conner et al, Obstet Gynecol 2014; 123:752-61 None. There are no data to suggest that at all.
Question 7:
Is there any role for use of a pessary as an adjunct to either 17 alpha-hydroxyprogesterone caproate or vaginal progestogen prophylaxis?
Response from Dr. Iams:
I don't know. The European data are interesting but not conclusive (see Iams, BJOG 2014 Mar; 121:463) . We consider a ring or cup pessary when there is progressive cervical shortening to 0 mm before 24 weeks in a woman with a history of two births prior to 26 weeks who is being treated with progestogen and already has a cerclage in place. I've done that four times in the last 3 years: one failed soon after, one was amazingly successful and led to birth at 38 weeks, one was removed 2 weeks later at 21 weeks for discomfort and spotting (she is now at 28 weeks), and the fourth one was placed recently at 18 weeks in a woman who is still pregnant.
Question 8:
What do you currently offer to the patient with a multifetal gestation and cervical shortening or history of preterm birth?
Response from Dr. Iams:
There are two risk factors at work in this setting. The first is uterine stretch, which can lead to a short cervix that is not dangerous, does not respond to "progestogen" treatment, and is often made worse by cerclage. The other is a history of a previous preterm birth, which often but not always means increased risk for recurrent preterm birth and is marked by a short cervix in the next pregnancy (see Iams JD et al, AJOG 1998; 178:1035-40 
